Background. Osteopontin (OPN) is an extracellularmatrix protein that is overexpressed in various cancers and promotes onco-genic features including cell proliferation, survival, migration, and angiogenesis. Here, we analyzed the correlation between the expression pattern of (osteopontin and CA15.3) and clinic-pathological status of breast cancer and other standard prognostic factors. Patients and methods. A case control study with 60 female breast cancer patients and 20 controls. All patients were subjected to complete medical history uptake , clinical examination and laboratory investigations include histopathological type of cancer, hormone receptor status ,CA 15-3 serum concentratios and osteopontin plasma level by ELISA. Results. Our study showed that osteopontin plasma level was significantly different among breast cancers and controls (p<0.0001) but no association between osteopontin plasma level and histological type , stage or grade. Also we found significant association between CA 15-3 and cancer stage (p<0.000). Interestingly CA15.3 serum concentrations increased in hormone receptor positive cancer. Conclusion. OPN and CA15.3 are overexpressed in breast cancer. OPN overexpression is associated with poor prognosis. Moreover CA15.3 has minimal prognostic value in non metastatic breast cancer.
Introduction
Breast cancer is the most common cause of cancer-related mortality in women in less developed regions, and the second most common (after lung cancer) in developed regions [1] [2] . It emerges through a multi-step process starting from hyperplasia to premalignant change, in situ carcinoma, and invasive breast cancer [3] . Up to 2013, breast cancer reportedly accounted for 29% of all new cancer cases and 14% of all cancer-related deaths among women worldwide . Breast cancer-related mortality is closely associated with the development of metastatic potential of the primary tumor. Despite the significant efforts to reduce breast cancer metastasis and mortality, its prognosis remains poor [4] .
Improvements in chemotherapy, surgery, lymph node evaluation and hormone receptor blocking therapy have successfully doubled the survival of breast cancer patients however it is still the leading cause of cancer-related mortality in women [5] [6]. It is a heterogeneous disease whose component includes many molecular subtypes [1] . Different molecular subtypes of breast cancer have various prognoses and responses to therapy [5] . Due to the heterogeneous clinical nature of breast cancer, it is necessary to identify new biomarkers that are associated with tumor growth, angiogenesis and metastasis [7] .
Serum tumor markers have been widely used as non-invasive tools for measuring treatment response, early diagnosis of recurrence and predicting prognosis. Breast 
Results
The current study was carried out on newly diagnosed 60 female breast cancer patients and 20 healthy controls the demographic data of patients and controls was summarized in Table 1 . The clinical Characteristics of breast cancer , osteopontin plasma level and CA15.3 serum concentrations were summarized in Table 2 . Our results showed higher osteopontin plasma level among patients than controls. But no difference in its level according to histological type of cancer , cancer stage or grade. Osteopontin plasma level was higher in ER-ve and PR-ve tumors than ER+ve and PR+ve tumors. Also, CA15.3 serum concentrations were higher in stage 2 and stage 3 than in stage 1. But showed no difference according to tumor grade. Interestingly CA15.3 serum concentrations were higher in ER+ve and PR+ve tumors than ER-ve and PR-ve tumors. [4] . It has been demonstrated that OPN is associated with more than 30 cancers so far and a marker for breast, cervical, colorectal, head and neck, liver, lung, ovarian and prostate cancers, as well as for sarcoma.
Abundant production of osteopontin is correlated with aggressiveness here we tested this hypothesis. We found that osteopontin plasma level was significantly higher in breast cancers than controls (p<0.0001) . Consistent with ,Liu et al [9] ,who found that OPN expression was significantly higher in human cancers tissues than in matched normal tissues . But there was no significant difference between patients and controls as regard to age , parity and menopausal status.
Also We found that there were no association between osteopontin plasma level and age ,parity or menopausal status. This finding is concordant with Xu et al. [4] , in their meta-analysis study found that there was no correlation between OPN expression and age (P=0.572) and between OPN expression and menopausal status ( p=0.688). Moreover osteopontin plasma level showed no correlation with histological subtype of cancer (p=0.27).This result is in concordance with, Thorat et al., [7] who found that OPN expression didn't correlate with histological subtype of cancer. In our study OPN plasma level didn't differ significantly by T stage(p=0.87). Similar to Thorat et al., [7] 
